1. Scrip
  2. >>R&D

Takeda Chooses PRA To Lead Its Revamped Clinical Development Ops

 
• By Sten Stovall

Takeda has chosen US-based PRA Health Sciences to lead its clinical development as part of the Japanese drug maker’s global R&D overhaul aimed at cutting costs and improving efficiency and innovation.

Scientist in lab

Having announced a major shakeup of its R&D operations in late July, Takeda Pharmaceutical Co. Ltd. has now chosen PRA Health Sciences Inc. to take control of the Japanese drug maker’s pipeline of clinical studies and related product progression.

The pact, which the duo described as ground-breaking, will see around 300 Takeda employees offered the chance to “transition” to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.

Shigella Vaccine Pipeline And Why It Matters

 
• By Vibha Ravi

A GSK-Bharat Biotech deal on a shigella vaccine candidate has cast a spotlight on the disease which is the second leading cause of diarrheal deaths in children below five. Scrip looks at data from Pharmaprojects, WHO and other sources to highlight why a vaccine matters and what pharma is doing

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: US policies in spotlight at BIO; Lilly’s Verve acquisition; UroGen’s bladder cancer approval; Ireland’s biopharma talent; and Korea proposes new AI R&D project.